Home › NDC Lookup › RxCUI directory › RxCUI 1731350

Deferoxamine mesylate 500 MG Injection — RxCUI 1731350

Name: Deferoxamine mesylate 500 MG Injection (RxCUI 1731350)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 1731350 Semantic clinical drug · SCD ● Current RxNorm concept 9 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1731350

Official nameDeferoxamine mesylate 500 MG Injection

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

FDA products mapped9

Package NDCs mapped9

Reported Medicaid activity (SDUD)5,720 prescriptions · 32 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Deferoxamine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It binds extra iron in your body. It's used alongside standard care for acute iron poisoning and to treat iron overload from repeated transfusions in chronic anemia. It isn't used...
That's expected. Deferoxamine and the iron it binds leave through your kidneys and can turn urine reddish. Still, tell your care team if you notice reduced urination.
Injection-site soreness, nausea or headache can happen. Call right away for vision or hearing changes, hives or swelling, trouble breathing, severe diarrhea or belly pain, or signs...
Only if your doctor says so. High-dose vitamin C has caused heart problems in people with severe iron overload. It's usually started after the first month, kept to a small amount,...

📖 Read our full Deferoxamine guide →

🕸️ Concept Web — How Deferoxamine mesylate 500 MG Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Deferoxamine mesylate 500 MG Injection RxCUI 1731350 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Deferoxamine 3131 IN
- Deferoxamine mesylate 3132 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Desferal 151607 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Deferoxamine Injection 1731344 SCDF
- Deferoxamine mesylate Injection 2646026 SCDFP
- Deferoxamine Injectable Product 1152154 SCDG
- Deferoxamine mesylate Injectable Product 2659820 SCDGP
- Deferoxamine Injection [Desferal] 1731347 SBDF
- Deferoxamine mesylate Injection [Desferal] 2655250 SBDFP
- Desferal Injectable Product 1174510 SBDG
- Injection 1649574 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Deferoxamine mesylate 500 MG 1731349 SCDC
- Deferoxamine mesylate 500 MG Injection [Desferal] 1731352 SBD
- Deferoxamine mesylate 500 MG [Desferal] 1731351 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Deferoxamine mesylate 500 MG SCDC · 1731349
Deferoxamine Injection SCDF · 1731344
Deferoxamine mesylate Injection SCDFP · 2646026
Deferoxamine Injectable Product SCDG · 1152154
Deferoxamine mesylate Injectable Product SCDGP · 2659820

Brand-Name Concepts

Deferoxamine mesylate 500 MG Injection [Desferal] SBD · 1731352
Deferoxamine mesylate 500 MG [Desferal] SBDC · 1731351
Deferoxamine Injection [Desferal] SBDF · 1731347
Deferoxamine mesylate Injection [Desferal] SBDFP · 2655250
Desferal Injectable Product SBDG · 1174510
Desferal BN · 151607

📦 FDA Products & Package NDCs

9 products · 9 package NDCs

9 package NDCs map to RxCUI 1731350 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00078-0467-91	4 VIAL in 1 CARTON (0078-0467-91) / 1 INJECTION, POWDER, LY...	Desferal	Novartis Pharmaceuticals Corporation	1968-04-02
00409-2337-25	4 VIAL, SINGLE-USE in 1 CARTON (0409-2337-25) / 1 INJECTION...	Deferoxamine Mesylate	Hospira, Inc.	2005-03-31
60505-6236-06	4 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (...	Deferoxamine mesylate	Apotex Corp.	2021-11-05
60505-6237-06	4 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (...	Deferoxamine mesylate	Apotex Corp.	2021-11-05
63323-0597-10	1 VIAL in 1 BOX (63323-597-10) / 5.3 mL in 1 VIAL	Deferoxamine	Fresenius Kabi USA, LLC	2009-12-15
63323-0599-30	1 VIAL in 1 BOX (63323-599-30) / 21.1 mL in 1 VIAL	Deferoxamine	Fresenius Kabi USA, LLC	2009-12-15
68083-0172-01	4 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (...	Deferoxamine mesylate	Gland Pharma Limited	2017-10-09
68083-0173-01	4 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (...	Deferoxamine mesylate	Gland Pharma Limited	2017-10-09
87081-0467-91	4 mL in 1 VIAL (87081-467-91)	Desferal	MITEM PHARMA	1968-04-02

Observed labelers: Apotex Corp. (2) · Fresenius Kabi USA, LLC (2) · Gland Pharma Limited (2) · Hospira, Inc. (1) · MITEM PHARMA (1) · Novartis Pharmaceuticals Corporation (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J0895	Deferoxamine mesylate inj	5	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.